Vascular Endothelial Effects of Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction
In this randomized double-blind clinical trial addressing mechanisms, sacubitril/valsartan lowered blood pressure and flicker-induced dilatation of retinal venules in patients with symptomatic HFrEF but did not improve endothelial function, retinal microvascular function, or arterial stiffness compared to valsartan monotherapy. (Differential Vascular and Endocrine Effects of Valsartan/Sacubitril in Heart Failure With Reduced Ejection Fraction [VASCEND]; NCT03168568).
Authors
- Thomas Haider (ORCID: https://orcid.org/0000-0002-3048-4662)
- Leonie Kreysing
- Matthias P. Nägele (ORCID: https://orcid.org/0000-0002-4065-6747)
- Jens Barthelmes (ORCID: https://orcid.org/0000-0003-1010-3436)
- Monika Hebeisen (ORCID: https://orcid.org/0000-0002-3843-1629)
- Valentina A. Rossi (ORCID: https://orcid.org/0000-0001-9235-6597)
- Delia Nebunu (ORCID: https://orcid.org/0000-0001-9226-4983)
- Andreas J. Flammer (ORCID: https://orcid.org/0000-0002-1373-0630)
- Isabella Sudano
- Frank Ruschitzka (ORCID: https://orcid.org/0000-0001-5972-0596)
Institutions
- University of Zurich (CH)
- University Hospital of Zurich (CH)
Publication Details
- Journal
- JACC Advances
- Published
- 2024-11-13
- DOI
- https://doi.org/10.1016/j.jacadv.2024.101392
- Primary Topic
- Blood Pressure and Hypertension Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Pfizer
- AstraZeneca
- Novartis
- Les Laboratories Pierre Fabre
- Universität Zürich
- Vifor Pharma